Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ANGIODYNAMICS INC (ANGO)

AngioDynamics FY2026 sales rise 9.4% to $320.2 million; net loss widens to $36.7 million

Mixed Impact 3 of 5 guidance Written later

AngioDynamics reported fiscal 2026 results for the year ended May 31, 2026, with pro forma net sales up 9.4% to $320.2 million and Med Tech sales up 18.4% to $150.0 million. The GAAP net loss widened to $36.7 million, or $0.88 per share, from $34.0 million, or $0.83, a year earlier, and the company issued fiscal 2027 guidance calling for net sales of $336.0 million to $341.0 million and adjusted loss per share of $0.29 to $0.24.

Key points

  • Fourth-quarter pro forma net sales were $86.6 million, up 8.0%, but the GAAP loss per share was $0.27 versus $0.15 a year earlier.
  • Full-year adjusted EBITDA was $13.2 million, compared with $7.6 million in the prior year.
  • Fiscal 2027 guidance: net sales of $336.0 million to $341.0 million and adjusted EPS of ($0.29) to ($0.24), compared with fiscal 2026 adjusted loss per share of $0.24.
  • The company ended fiscal 2026 with $53.9 million in cash and states it has a debt-free balance sheet.

The filing

CompanyANGIODYNAMICS INC (ANGO)
Form8-K, current report
Filed with the SECJul 14, 2026, 7:30 AM ET
Accession number0001140361-26-028368

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.